Advertisement
Australia markets closed
  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     
  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     
  • AUD/USD

    0.6546
    +0.0022 (+0.34%)
     
  • OIL

    84.19
    +0.62 (+0.74%)
     
  • GOLD

    2,354.90
    +12.40 (+0.53%)
     
  • Bitcoin AUD

    98,444.73
    +368.34 (+0.38%)
     
  • CMC Crypto 200

    1,388.81
    -7.73 (-0.55%)
     
  • AUD/EUR

    0.6100
    +0.0027 (+0.44%)
     
  • AUD/NZD

    1.0991
    +0.0034 (+0.31%)
     
  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     
  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     
  • FTSE

    8,115.73
    +36.87 (+0.46%)
     
  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     
  • DAX

    18,053.89
    +136.61 (+0.76%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Company News For Nov 21, 2019

  • Shares of Urban Outfitters, Inc. URBN plunged 15.2% after the company reported third-quarter fiscal 2020 earnings of $0.56, misseing the Zacks Consensus Estimates of $0.57

  • Shares of Kiniksa Pharmaceuticals, Ltd. KNSA soared 28.7% after the company received FDA breakthrough therapy designation for the Rilonacept to treat recurrent pericarditis

  • Shares of Aurora Cannabis Inc. ACB added 12.8% after the company announced the addition of a Chief Product Officer and Chief Integration Officer to strengthen its leadership

  • Shares of Endo International plc ENDP gained 4.9% after the company announced that FDA has agreed to review the original Biologics License Application for collagenase clostridium histolyticum


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Endo International plc (ENDP) : Free Stock Analysis Report
 
Urban Outfitters, Inc. (URBN) : Free Stock Analysis Report
 
Kiniksa Pharmaceuticals, Ltd. (KNSA) : Free Stock Analysis Report
 
Aurora Cannabis Inc. (ACB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research